Journal: bioRxiv

Article Title: Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates

doi: 10.1101/2021.05.15.444262

Figure Lengend Snippet:

Article Snippet: Following fixation, an in situ ELISA was performed for the detection of SARS-CoV-2 NP antigen using an anti-SARS-COV-2, MERS, SARS-CoV NP primary antibody (EastCoast Bio; ME, USA) and a Goat Anti-Mouse IgG conjugate antibody (Fitzgerald; MA USA).

Techniques: Infection

Journal: bioRxiv

Article Title: Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates

doi: 10.1101/2021.05.15.444262

Figure Lengend Snippet: in rhesus macaques vaccinated with one or two dose(s) of CoVLP, CoVLP+CpG or CoVLP+AS03. Equivalent (Eq.) viral copy (VC) of subgenomic E gene RNA in nasal swabs ( A ) and subgenomic N gene RNA BAL ( B ) were measured by real time PCR. The dotted line represents the limit of detection of the method. Samples below the limit of detection were assigned a value of 250 Eq. VC/mL for graphical representation. SARS-CoV-2 infected cells measured by immunohistochemistry ( C ). Individual data and median (line) are represented.

Article Snippet: Following fixation, an in situ ELISA was performed for the detection of SARS-CoV-2 NP antigen using an anti-SARS-COV-2, MERS, SARS-CoV NP primary antibody (EastCoast Bio; ME, USA) and a Goat Anti-Mouse IgG conjugate antibody (Fitzgerald; MA USA).

Techniques: Real-time Polymerase Chain Reaction, Infection, Immunohistochemistry

Journal: bioRxiv

Article Title: Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates

doi: 10.1101/2021.05.15.444262

Figure Lengend Snippet: collected six days post-challenge with SARS-CoV-2 from rhesus macaques immunized with two doses of CoVLP, CoVLP+CpG or CoVLP+AS03. Dotted lines indicate the LOD for each cytokine/chemokine. Individual data, median (line) and 75th/25th interquartile (box) are represented. Statistical comparisons were performed using a non-parametric Kruskal-Wallis test. The Dunn post-hoc multiple comparisons test was used (* p < 0.05).

Article Snippet: Following fixation, an in situ ELISA was performed for the detection of SARS-CoV-2 NP antigen using an anti-SARS-COV-2, MERS, SARS-CoV NP primary antibody (EastCoast Bio; ME, USA) and a Goat Anti-Mouse IgG conjugate antibody (Fitzgerald; MA USA).

Techniques: